Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group.

Abstract

Fourteen patients with metastatic renal adenocarcinoma without prior chemotherapy were treated with 1,2,4-triglycidylurazol (TGU, NSC-332488), a new triepoxide alkylating agent. TGU was chosen for this study among other triepoxides because of its high antitumour activity in animal models, its relatively good water solubility and the expected favourable therapeutic index. The starting dose was 800 mg/m2 i.v. (600 mg/m2 for patients with prior extensive radiotherapy) every 4 weeks. No objective tumour regression was seen in this favourable group of patients. Leuko- and thrombocytopenia were the most important side-effects. Severe cumulative and prolonged thrombocytopenia was seen. Other toxicities observed were nausea with or without vomiting in all patients and local phlebitis in some.

• Authors: U Bruntsch, P Dodion, W W Ten Bokkel Huinink, H H Hansen, H M Pinedo, M Hansen, J Renard, M Van Glabbeke
• Journal: European journal of cancer & clinical oncology (Eur J Cancer Clin Oncol) Vol. 22 Issue 6 Pg. 697-9 (Jun 1986) ISSN: 0277-5379 [Print] England
• PMID: 3743605 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Triazoles
• anaxirone

Topics

• Adenocarcinoma (drug therapy)
• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Drug Evaluation
• Female
• Humans
• Kidney Neoplasms (drug therapy)
• Leukopenia (chemically induced)
• Male
• Middle Aged
• Thrombocytopenia (chemically induced)
• Triazoles (administration & dosage, adverse effects, therapeutic use)